US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Mira Pharma

0.7636

+0.05357.53%

Post-market: 0.7500-0.0136-1.78%19:30 EDT

Volume:117.40K

Turnover:92.91K

Market Cap:31.98M

PE:-0.53

High:0.8200

Open:0.7200

Low:0.7200

Close:0.7101

52wk High:2.45

52wk Low:0.6000

Shares:41.88M

Float Shares:34.94M

Volume Ratio:2.27

T/O Rate:0.34%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-1.4419

EPS(LYR):-1.3505

ROE:-217.12%

ROA:-129.55%

PB:3.92

PE(LYR):-0.57

Loading ...

Overview Company News Filings

MIRA Pharmaceuticals Appoints New Fractional Chief Financial Officer

BRIEF-Mira Pharmaceuticals - Alan Weichselbaum To Step Down As CFO Effective June 6, 2026 - SEC Filing

Mira Pharmaceuticals names Andriy Mushak fractional CFO, replacing Alan Weichselbaum

MIRA Pharmaceuticals Secures Unified Global Rights to Pipeline

Mira Pharmaceuticals Inc: Controls Global Development Rights Across Entire Pipeline

THOMSON REUTERS

Mira Pharmaceuticals secures worldwide exclusive rights to MIRA-55 and SKNY-1 in amended license deal

MIRA Expands Global Ketamir-2 License for Clinical Development

Mira Pharmaceuticals Inc: Entered Into Amendment No 1 to Exclusive License Agreement With Miralogx Llc - SEC Filing

THOMSON REUTERS

Mira Pharmaceuticals Inc - Expands Ketamir-2 Patent Portfolio to 10 Major Markets - SEC Filing

THOMSON REUTERS

Mira Pharmaceuticals expands Ketamir-2 license to worldwide rights across 10 major markets

Mira Pharmaceuticals management to meet with Maxim

Mira Pharmaceuticals Q1 net loss narrows to $1.15 million; revenue flat at no revenue

MIRA Pharmaceuticals Reports Positive Phase 1 Ketamir-2 Results

Mira Pharmaceuticals publishes investor presentation on Ketamir-2 for chemotherapy-induced peripheral neuropathy

Mira Pharma reports positive Phase 1 results for Ketamir-2 oral NMDA modulator

Mira announces acceptance of peer-reviewed SKNY-1 manuscript

MIRA highlights SKNY-1 preclinical data in new publication

Mira Pharmaceuticals reports peer-reviewed preclinical study on obesity candidate SKNY-1

Mira Pharmaceuticals investor presentation highlights Ketamir-2 advancing to Phase 2a neuropathic pain trial

Mira Pharmaceuticals FY25 net loss widens to $10 million

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/stock/MIRA/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"MIRA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MIRA\",,,,,undefined,":{"symbol":"MIRA","market":"US","secType":"STK","nameCN":"Mira Pharma","latestPrice":0.7636,"timestamp":1787342400000,"preClose":0.7101,"halted":0,"volume":117396,"hourTrading":{"tag":"盘后","latestPrice":0.75,"preClose":0.7636,"latestTime":"19:30 EDT","volume":1183,"amount":888.9174,"timestamp":1787355006535,"change":-0.0136,"changeRate":-0.01781,"amplitude":0.01781},"delay":0,"changeRate":0.0753415011970145,"floatShares":34944200,"shares":41876087,"eps":-1.4419,"marketStatus":"Market Closed","change":0.0535,"latestTime":"08-21 16:00:00 EDT","open":0.72,"high":0.82,"low":0.72,"amount":92910.1293,"amplitude":0.140825,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.4419,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1787558400000},"marketStatusCode":7,"adr":0,"listingDate":1691035200000,"exchange":"NASDAQ","adjPreClose":0.7101,"preHourTrading":{"tag":"盘前","latestPrice":0.73,"preClose":0.7101,"latestTime":"09:00 EDT","volume":1780,"amount":1299.053434,"timestamp":1787317257193,"change":0.0199,"changeRate":0.028024,"amplitude":0.036192},"postHourTrading":{"tag":"盘后","latestPrice":0.75,"preClose":0.7636,"latestTime":"19:30 EDT","volume":1183,"amount":888.9174,"timestamp":1787355006535,"change":-0.0136,"changeRate":-0.01781,"amplitude":0.01781},"volumeRatio":2.2679607784245994},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MIRA\",,,,,undefined,":{"symbol":"MIRA","floatShares":34944200,"roa":"-129.55%","roe":"-217.12%","lyrEps":-1.350504,"volumeRatio":2.2679607784245994,"shares":41876087,"dividePrice":0,"high":0.82,"amplitude":0.140825,"preClose":0.7101,"low":0.72,"week52Low":0.6,"pbRate":"3.92","week52High":2.45,"institutionHeld":0,"latestPrice":0.7636,"eps":-1.4419,"divideRate":0,"volume":117396,"delay":0,"ttmEps":-1.4419,"open":0.72,"prevYearClose":1.51,"prevWeekClose":0.7802,"prevMonthClose":0.792,"prevQuarterClose":0.9465,"fiveDayClose":0.7802,"twentyDayClose":0.8818,"sixtyDayClose":1.155},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MIRA\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-12","symbol":"MIRA","fiscalQuarterEnding":"2026/06","expectedEps":null,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1786507200000,"reportTimeType":"post","actualEps":-0.03},{"market":"US","date":"2026-05-14","symbol":"MIRA","fiscalQuarterEnding":"2026/03","expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1778731200000,"reportTimeType":"","actualEps":-0.03},{"date":"2026-03-31","symbol":"MIRA","type":"earning","reportTimeType":"","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1774944000000,"name":null,"time":"","dateTimestamp":1774929600000,"actualEps":null},{"market":"US","date":"2025-11-13","symbol":"MIRA","fiscalQuarterEnding":"2025/09","expectedEps":null,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1763010000000,"reportTimeType":"pre","actualEps":-1.18},{"market":"US","date":"2025-08-14","symbol":"MIRA","fiscalQuarterEnding":"2025/06","expectedEps":-0.11,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1755144000000,"reportTimeType":"post","actualEps":-0.09}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MIRA\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"MIRA\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/MIRA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"MIRA","date":"2026-08-21","current":-0.529579,"percent":0.47832,"low":-15.501022,"twenty":-6.515788,"median":-2.930145,"eighty":-1.709075,"high":-0.648567,"avg":-3.991571,"sd":3.123833,"marketCap":29839883},"quantilePoints":[{"date":"2023-08-04","current":-15.501022,"twenty":-15.501022,"median":-15.501022,"eighty":-15.501022,"marketCap":109409161},{"date":"2023-08-11","current":-14.407729,"twenty":-14.826558,"median":-14.407729,"eighty":-13.088417,"marketCap":101692488},{"date":"2023-08-18","current":-13.611953,"twenty":-14.407729,"median":-13.779485,"eighty":-13.130299,"marketCap":96075752},{"date":"2023-08-25","current":-13.193124,"twenty":-14.407729,"median":-13.42348,"eighty":-13.109358,"marketCap":93119575},{"date":"2023-09-01","current":-13.137838,"twenty":-14.303022,"median":-13.371126,"eighty":-13.130299,"marketCap":92729360},{"date":"2023-09-07","current":-12.209294,"twenty":-13.9889,"median":-13.365891,"eighty":-13.071664,"marketCap":86175515},{"date":"2023-09-15","current":-7.434221,"twenty":-13.678966,"median":-13.193124,"eighty":-12.686741,"marketCap":52472141},{"date":"2023-09-22","current":-11.507289,"twenty":-13.511434,"median":-13.119829,"eighty":-11.928492,"marketCap":66366173},{"date":"2023-09-29","current":-12.263336,"twenty":-13.419292,"median":-13.046534,"eighty":-11.42538,"marketCap":70726534},{"date":"2023-10-06","current":-12.045492,"twenty":-13.402539,"median":-12.816178,"eighty":-11.507289,"marketCap":69470159},{"date":"2023-10-13","current":-7.586097,"twenty":-13.383691,"median":-12.460173,"eighty":-11.225373,"marketCap":43751419},{"date":"2023-10-20","current":-8.457473,"twenty":-13.371126,"median":-12.263336,"eighty":-10.752267,"marketCap":48776920},{"date":"2023-10-27","current":-6.022746,"twenty":-13.371126,"median":-12.209294,"eighty":-9.627991,"marketCap":34735079},{"date":"2023-11-03","current":-3.818677,"twenty":-13.36275,"median":-12.045492,"eighty":-8.098671,"marketCap":22023518},{"date":"2023-11-10","current":-3.793048,"twenty":-13.343902,"median":-11.968606,"eighty":-7.418465,"marketCap":21875709},{"date":"2023-11-17","current":-6.622011,"twenty":-13.222442,"median":-11.712319,"eighty":-5.991992,"marketCap":49959391},{"date":"2023-11-24","current":-6.405718,"twenty":-13.159952,"median":-11.404903,"eighty":-6.252529,"marketCap":48327581},{"date":"2023-12-01","current":-6.955071,"twenty":-13.133315,"median":-11.148487,"eighty":-6.405718,"marketCap":52472141},{"date":"2023-12-08","current":-3.546106,"twenty":-13.117734,"median":-10.762135,"eighty":-5.961237,"marketCap":26753401},{"date":"2023-12-15","current":-2.977946,"twenty":-13.096793,"median":-9.110163,"eighty":-5.156496,"marketCap":22466945},{"date":"2023-12-22","current":-2.066929,"twenty":-13.063287,"median":-8.611245,"eighty":-3.869935,"marketCap":15593833},{"date":"2023-12-29","current":-2.155092,"twenty":-13.025592,"median":-8.1243,"eighty":-3.839181,"marketCap":16258973},{"date":"2024-01-05","current":-2.272643,"twenty":-12.962768,"median":-7.893642,"eighty":-3.762396,"marketCap":17145826},{"date":"2024-01-12","current":-1.929591,"twenty":-12.874813,"median":-7.640782,"eighty":-3.079823,"marketCap":14557693},{"date":"2024-01-19","current":-1.608482,"twenty":-12.807801,"median":-7.444864,"eighty":-2.883906,"marketCap":12135106},{"date":"2024-01-26","current":-2.292235,"twenty":-12.642964,"median":-7.355439,"eighty":-2.366683,"marketCap":17293635},{"date":"2024-02-02","current":-1.880808,"twenty":-12.498268,"median":-7.111805,"eighty":-2.256969,"marketCap":14189649},{"date":"2024-02-09","current":-1.950359,"twenty":-12.397348,"median":-6.788541,"eighty":-2.206031,"marketCap":14714371},{"date":"2024-02-16","current":-2.01795,"twenty":-12.300188,"median":-6.405718,"eighty":-2.186439,"marketCap":15224311},{"date":"2024-02-23","current":-2.076725,"twenty":-12.241719,"median":-6.022746,"eighty":-2.135501,"marketCap":15667738},{"date":"2024-03-01","current":-1.968971,"twenty":-12.205282,"median":-5.750179,"eighty":-2.104154,"marketCap":14854789},{"date":"2024-03-08","current":-1.86102,"twenty":-12.137755,"median":-4.971969,"eighty":-2.061052,"marketCap":14040362},{"date":"2024-03-15","current":-2.409785,"twenty":-12.045492,"median":-3.957585,"eighty":-2.070847,"marketCap":18180488},{"date":"2024-03-22","current":-2.46856,"twenty":-12.014738,"median":-3.869935,"eighty":-2.084562,"marketCap":18623915},{"date":"2024-03-28","current":-2.135501,"twenty":-11.968606,"median":-3.818677,"eighty":-2.096317,"marketCap":16111164},{"date":"2024-04-05","current":-1.258227,"twenty":-11.958355,"median":-3.592948,"eighty":-2.059093,"marketCap":15076502},{"date":"2024-04-12","current":-1.209008,"twenty":-11.917349,"median":-3.095496,"eighty":-2.037542,"marketCap":14486745},{"date":"2024-04-19","current":-1.033719,"twenty":-11.835337,"median":-3.026925,"eighty":-1.978767,"marketCap":12386381},{"date":"2024-04-26","current":-1.1102,"twenty":-11.507289,"median":-2.977946,"eighty":-1.941738,"marketCap":13302796},{"date":"2024-05-03","current":-0.996589,"twenty":-11.466334,"median":-2.723253,"eighty":-1.872971,"marketCap":11941476},{"date":"2024-05-10","current":-0.925167,"twenty":-11.297339,"median":-2.546927,"eighty":-1.840684,"marketCap":11085663},{"date":"2024-05-17","current":-0.812651,"twenty":-11.251002,"median":-2.419581,"eighty":-1.782849,"marketCap":10043611},{"date":"2024-05-24","current":-1.05244,"twenty":-11.138236,"median":-2.390193,"eighty":-1.612165,"marketCap":13007178},{"date":"2024-05-31","current":-0.956764,"twenty":-11.09723,"median":-2.331418,"eighty":-1.319904,"marketCap":11824708},{"date":"2024-06-07","current":-0.922081,"twenty":-10.81147,"median":-2.30203,"eighty":-1.233679,"marketCap":11396062},{"date":"2024-06-14","current":-0.849247,"twenty":-10.732533,"median":-2.292235,"eighty":-1.18937,"marketCap":10495906},{"date":"2024-06-21","current":-0.875439,"twenty":-10.189973,"median":-2.272643,"eighty":-1.090284,"marketCap":10819607},{"date":"2024-06-28","current":-0.77737,"twenty":-9.841423,"median":-2.272643,"eighty":-1.073193,"marketCap":9607575},{"date":"2024-07-05","current":-0.687674,"twenty":-9.256415,"median":-2.262847,"eighty":-1.05424,"marketCap":8499008},{"date":"2024-07-12","current":-0.717692,"twenty":-8.841445,"median":-2.213868,"eighty":-1.045463,"marketCap":8870009},{"date":"2024-07-15","current":-0.704656,"twenty":-8.774265,"median":-2.213868,"eighty":-1.033719,"marketCap":8708897},{"date":"2024-08-02","current":-2.906169,"twenty":-8.772416,"median":-2.213868,"eighty":-1.036655,"marketCap":35917550},{"date":"2024-08-09","current":-2.535423,"twenty":-8.703509,"median":-2.262847,"eighty":-1.048424,"marketCap":31335476},{"date":"2024-08-16","current":-2.173611,"twenty":-8.390838,"median":-2.272643,"eighty":-1.04904,"marketCap":27788063},{"date":"2024-08-23","current":-2.162049,"twenty":-8.098671,"median":-2.248016,"eighty":-1.051378,"marketCap":27640254},{"date":"2024-08-30","current":-2.162049,"twenty":-7.95515,"median":-2.242981,"eighty":-1.05289,"marketCap":27640254},{"date":"2024-09-06","current":-1.826758,"twenty":-7.791127,"median":-2.23142,"eighty":-1.05469,"marketCap":23353798},{"date":"2024-09-13","current":-1.549276,"twenty":-7.650578,"median":-2.222644,"eighty":-1.05842,"marketCap":19806385},{"date":"2024-09-20","current":-1.341164,"twenty":-7.640782,"median":-2.194276,"eighty":-1.060611,"marketCap":17145826},{"date":"2024-09-27","current":-1.237108,"twenty":-7.586097,"median":-2.16783,"eighty":-1.073193,"marketCap":15815546},{"date":"2024-10-04","current":-1.352726,"twenty":-7.444864,"median":-2.155092,"eighty":-1.083185,"marketCap":17293635},{"date":"2024-10-11","current":-1.24867,"twenty":-7.434221,"median":-2.147009,"eighty":-1.095016,"marketCap":15963355},{"date":"2024-10-18","current":-1.260232,"twenty":-7.355439,"median":-2.135501,"eighty":-1.1102,"marketCap":16111164},{"date":"2024-10-25","current":-1.437761,"twenty":-7.355439,"median":-2.125705,"eighty":-1.110817,"marketCap":18380747},{"date":"2024-10-31","current":-2.79918,"twenty":-7.270245,"median":-2.125705,"eighty":-1.18937,"marketCap":35785525},{"date":"2024-11-08","current":-2.150279,"twenty":-7.139233,"median":-2.135501,"eighty":-1.21299,"marketCap":27489790},{"date":"2024-11-15","current":-2.170683,"twenty":-7.064784,"median":-2.135501,"eighty":-1.218696,"marketCap":24399222},{"date":"2024-11-22","current":-1.856409,"twenty":-6.974663,"median":-2.135501,"eighty":-1.224412,"marketCap":20866673},{"date":"2024-11-29","current":-1.90061,"twenty":-6.755235,"median":-2.115909,"eighty":-1.229612,"marketCap":21363499},{"date":"2024-12-06","current":-1.753275,"twenty":-6.551481,"median":-2.101597,"eighty":-1.233136,"marketCap":19707413},{"date":"2024-12-13","current":-1.650142,"twenty":-6.445215,"median":-2.081117,"eighty":-1.235736,"marketCap":18548154},{"date":"2024-12-20","current":-1.473341,"twenty":-6.405718,"median":-2.071827,"eighty":-1.237108,"marketCap":16560852},{"date":"2024-12-27","current":-1.768009,"twenty":-6.252529,"median":-2.060335,"eighty":-1.241733,"marketCap":19873022},{"date":"2025-01-03","current":-1.694342,"twenty":-5.991992,"median":-2.057134,"eighty":-1.250581,"marketCap":19044979},{"date":"2025-01-10","current":-1.959543,"twenty":-5.868974,"median":-2.057134,"eighty":-1.258227,"marketCap":22025933},{"date":"2025-01-17","current":-1.768009,"twenty":-5.779566,"median":-2.037542,"eighty":-1.258227,"marketCap":19873022},{"date":"2025-01-24","current":-1.664875,"twenty":-5.732546,"median":-2.035768,"eighty":-1.259831,"marketCap":18713762},{"date":"2025-01-31","current":-1.856409,"twenty":-5.367769,"median":-2.010846,"eighty":-1.260232,"marketCap":20866673},{"date":"2025-02-07","current":-1.723809,"twenty":-5.033478,"median":-1.997597,"eighty":-1.260232,"marketCap":19376196},{"date":"2025-02-14","current":-1.753275,"twenty":-4.268723,"median":-1.967235,"eighty":-1.268496,"marketCap":19707413},{"date":"2025-02-21","current":-1.635408,"twenty":-4.064306,"median":-1.959359,"eighty":-1.271301,"marketCap":18382545},{"date":"2025-02-28","current":-1.502808,"twenty":-3.940055,"median":-1.950359,"eighty":-1.271793,"marketCap":16892069},{"date":"2025-03-07","current":-1.488074,"twenty":-3.869935,"median":-1.934829,"eighty":-1.271793,"marketCap":16726460},{"date":"2025-03-14","current":-1.841676,"twenty":-3.869935,"median":-1.920187,"eighty":-1.27873,"marketCap":20701065},{"date":"2025-03-21","current":-1.797476,"twenty":-3.846869,"median":-1.893243,"eighty":-1.290292,"marketCap":20204239},{"date":"2025-03-28","current":-1.620675,"twenty":-3.823803,"median":-1.885876,"eighty":-1.294917,"marketCap":18216937},{"date":"2025-04-04","current":-1.927027,"twenty":-3.8033,"median":-1.893243,"eighty":-1.309909,"marketCap":15132288},{"date":"2025-04-11","current":-1.806267,"twenty":-3.701093,"median":-1.885876,"eighty":-1.319904,"marketCap":14183998},{"date":"2025-04-17","current":-2.291021,"twenty":-3.602316,"median":-1.885876,"eighty":-1.323783,"marketCap":17990609},{"date":"2025-04-25","current":-2.128723,"twenty":-3.467739,"median":-1.885876,"eighty":-1.330657,"marketCap":16716134},{"date":"2025-05-02","current":-2.440901,"twenty":-3.248312,"median":-1.90061,"eighty":-1.333733,"marketCap":19167565},{"date":"2025-05-09","current":-2.676427,"twenty":-3.087659,"median":-1.92061,"eighty":-1.335972,"marketCap":21017067},{"date":"2025-05-16","current":-3.015077,"twenty":-3.060231,"median":-1.929591,"eighty":-1.33782,"marketCap":23875388},{"date":"2025-05-23","current":-2.611651,"twenty":-3.060231,"median":-1.942197,"eighty":-1.340821,"marketCap":20680794},{"date":"2025-05-30","current":-2.845213,"twenty":-3.032803,"median":-1.954767,"eighty":-1.341164,"marketCap":22530296},{"date":"2025-06-06","current":-2.927246,"twenty":-3.016719,"median":-1.959543,"eighty":-1.343476,"marketCap":23179883},{"date":"2025-06-13","current":-2.649478,"twenty":-3.012039,"median":-1.970481,"eighty":-1.352726,"marketCap":20980332},{"date":"2025-06-20","current":-2.628111,"twenty":-2.999889,"median":-1.99311,"eighty":-1.352726,"marketCap":20811136},{"date":"2025-06-27","current":-2.585377,"twenty":-2.991346,"median":-2.003743,"eighty":-1.36142,"marketCap":20472743},{"date":"2025-07-03","current":-2.564011,"twenty":-2.980626,"median":-2.014046,"eighty":-1.36845,"marketCap":20303547},{"date":"2025-07-11","current":-2.564011,"twenty":-2.973678,"median":-2.023876,"eighty":-1.374721,"marketCap":20303547},{"date":"2025-07-18","current":-4.711669,"twenty":-3.002927,"median":-2.037346,"eighty":-1.385099,"marketCap":37310135},{"date":"2025-07-25","current":-4.058566,"twenty":-3.076478,"median":-2.047338,"eighty":-1.397154,"marketCap":32138433},{"date":"2025-08-01","current":-3.84864,"twenty":-3.389372,"median":-2.057134,"eighty":-1.420873,"marketCap":30476100},{"date":"2025-08-08","current":-3.195538,"twenty":-3.551253,"median":-2.064723,"eighty":-1.428551,"marketCap":25304398},{"date":"2025-08-15","current":-3.428789,"twenty":-3.546261,"median":-2.076725,"eighty":-1.436037,"marketCap":27151435},{"date":"2025-08-22","current":-3.438101,"twenty":-3.551253,"median":-2.088717,"eighty":-1.466225,"marketCap":26697041},{"date":"2025-08-29","current":-3.438101,"twenty":-3.546261,"median":-2.106877,"eighty":-1.473341,"marketCap":26697041},{"date":"2025-09-05","current":-3.388985,"twenty":-3.525507,"median":-2.115909,"eighty":-1.473341,"marketCap":26315654},{"date":"2025-09-12","current":-4.076606,"twenty":-3.546416,"median":-2.135501,"eighty":-1.477279,"marketCap":31655062},{"date":"2025-09-19","current":-3.118849,"twenty":-3.546416,"median":-2.135501,"eighty":-1.484806,"marketCap":24218030},{"date":"2025-09-26","current":-3.192522,"twenty":-3.525507,"median":-2.152685,"eighty":-1.488074,"marketCap":24790109},{"date":"2025-10-03","current":-3.290754,"twenty":-3.49704,"median":-2.155092,"eighty":-1.488074,"marketCap":25552882},{"date":"2025-10-10","current":-3.290754,"twenty":-3.487217,"median":-2.162526,"eighty":-1.49011,"marketCap":25552882},{"date":"2025-10-17","current":-4.420416,"twenty":-3.487217,"median":-2.173611,"eighty":-1.498272,"marketCap":34324767},{"date":"2025-10-24","current":-3.806469,"twenty":-3.546416,"median":-2.185002,"eighty":-1.502808,"marketCap":29557438},{"date":"2025-10-31","current":-4.424118,"twenty":-3.578069,"median":-2.201174,"eighty":-1.502808,"marketCap":34353519},{"date":"2025-11-07","current":-3.861049,"twenty":-3.670695,"median":-2.213868,"eighty":-1.502941,"marketCap":29981253},{"date":"2025-11-14","current":-3.592921,"twenty":-3.756896,"median":-2.228568,"eighty":-1.509966,"marketCap":27899222},{"date":"2025-11-21","current":-8.242291,"twenty":-3.823803,"median":-2.23142,"eighty":-1.516361,"marketCap":56532717},{"date":"2025-11-28","current":-9.035993,"twenty":-3.856085,"median":-2.234472,"eighty":-1.529328,"marketCap":61976608},{"date":"2025-12-05","current":-9.035993,"twenty":-3.871153,"median":-2.253051,"eighty":-1.547915,"marketCap":61976608},{"date":"2025-12-12","current":-8.913885,"twenty":-3.914675,"median":-2.269374,"eighty":-1.5539,"marketCap":61139087},{"date":"2025-12-19","current":-9.829695,"twenty":-4.017922,"median":-2.272643,"eighty":-1.561199,"marketCap":67420500},{"date":"2025-12-26","current":-9.646533,"twenty":-4.0559,"median":-2.289228,"eighty":-1.564688,"marketCap":66164217},{"date":"2026-01-02","current":-9.219155,"twenty":-4.092912,"median":-2.292235,"eighty":-1.576475,"marketCap":63232891},{"date":"2026-01-09","current":-9.097047,"twenty":-4.198517,"median":-2.30203,"eighty":-1.591208,"marketCap":62395369},{"date":"2026-01-16","current":-8.913885,"twenty":-4.420416,"median":-2.331418,"eighty":-1.608482,"marketCap":61139087},{"date":"2026-01-23","current":-8.791777,"twenty":-4.493832,"median":-2.353856,"eighty":-1.618236,"marketCap":60301565},{"date":"2026-01-30","current":-7.63175,"twenty":-5.033478,"median":-2.394135,"eighty":-1.620675,"marketCap":52345108},{"date":"2026-02-06","current":-6.899102,"twenty":-5.899728,"median":-2.409785,"eighty":-1.620675,"marketCap":47319978},{"date":"2026-02-13","current":-7.204372,"twenty":-6.527971,"median":-2.415958,"eighty":-1.620675,"marketCap":49413782},{"date":"2026-02-20","current":-7.357007,"twenty":-6.994254,"median":-2.434454,"eighty":-1.620675,"marketCap":50460684},{"date":"2026-02-27","current":-8.120183,"twenty":-7.204372,"median":-2.451707,"eighty":-1.624409,"marketCap":55695195},{"date":"2026-03-06","current":-7.204372,"twenty":-7.265426,"median":-2.476142,"eighty":-1.628884,"marketCap":49413782},{"date":"2026-03-13","current":-7.265426,"twenty":-7.265426,"median":-2.483724,"eighty":-1.633328,"marketCap":49832543},{"date":"2026-03-20","current":-6.227508,"twenty":-7.289848,"median":-2.50832,"eighty":-1.638966,"marketCap":42713608},{"date":"2026-03-27","current":-6.471724,"twenty":-7.265426,"median":-2.523464,"eighty":-1.64662,"marketCap":44388652},{"date":"2026-04-02","current":-6.471724,"twenty":-7.265426,"median":-2.535423,"eighty":-1.650142,"marketCap":44388652},{"date":"2026-04-10","current":-4.104629,"twenty":-7.265426,"median":-2.555697,"eighty":-1.650142,"marketCap":42862528},{"date":"2026-04-17","current":-4.225354,"twenty":-7.258834,"median":-2.564011,"eighty":-1.656035,"marketCap":44123191},{"date":"2026-04-24","current":-4.225354,"twenty":-7.231117,"median":-2.577374,"eighty":-1.664875,"marketCap":44123191},{"date":"2026-05-01","current":-4.225354,"twenty":-7.204372,"median":-2.585377,"eighty":-1.664875,"marketCap":44123191},{"date":"2026-05-08","current":-4.024146,"twenty":-7.204372,"median":-2.587897,"eighty":-1.670768,"marketCap":42022087},{"date":"2026-05-15","current":-3.923945,"twenty":-7.17995,"median":-2.606744,"eighty":-1.679608,"marketCap":40975737},{"date":"2026-05-22","current":-4.233115,"twenty":-7.130713,"median":-2.612193,"eighty":-1.679608,"marketCap":41522024},{"date":"2026-05-29","current":-4.626823,"twenty":-7.105897,"median":-2.638795,"eighty":-1.679608,"marketCap":45383853},{"date":"2026-06-05","current":-4.541141,"twenty":-7.082264,"median":-2.660161,"eighty":-1.679608,"marketCap":44543412},{"date":"2026-06-12","current":-4.112732,"twenty":-7.082264,"median":-2.670844,"eighty":-1.679608,"marketCap":40341203},{"date":"2026-06-18","current":-4.190702,"twenty":-7.082264,"median":-2.675889,"eighty":-1.679608,"marketCap":41106005},{"date":"2026-06-26","current":-3.888674,"twenty":-7.053029,"median":-2.726776,"eighty":-1.685086,"marketCap":38143448},{"date":"2026-07-02","current":-4.058324,"twenty":-6.974663,"median":-2.734945,"eighty":-1.687431,"marketCap":39807523},{"date":"2026-07-10","current":-3.941368,"twenty":-6.910296,"median":-2.756312,"eighty":-1.693077,"marketCap":38660320},{"date":"2026-07-17","current":-4.00006,"twenty":-6.87468,"median":-2.79918,"eighty":-1.694342,"marketCap":39236022},{"date":"2026-07-24","current":-3.975212,"twenty":-6.844153,"median":-2.845213,"eighty":-1.694342,"marketCap":38992294},{"date":"2026-07-31","current":-3.497107,"twenty":-6.801416,"median":-2.857082,"eighty":-1.694342,"marketCap":34302629},{"date":"2026-08-07","current":-2.905474,"twenty":-6.684004,"median":-2.866446,"eighty":-1.700426,"marketCap":28499379},{"date":"2026-08-14","current":-3.325088,"twenty":-6.568471,"median":-2.905822,"eighty":-1.707238,"marketCap":31520767},{"date":"2026-08-21","current":-3.147773,"twenty":-6.515788,"median":-2.930145,"eighty":-1.709075,"marketCap":29839883}],"updateTime":1787476009522},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"MIRA\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2642437154","title":"MIRA Pharmaceuticals Appoints New Fractional Chief Financial Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2642437154","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642437154?lang=en_us&edition=fundamental","pubTime":"2026-06-09 06:44","pubTimestamp":1780958645,"startTime":"0","endTime":"0","summary":"MIRA Pharmaceuticals, Inc. ( ($MIRA) ) has issued an announcement. On June 6, 2026, MIRA Pharmaceuticals, Inc. implemented a leadership change in i...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/mira-pharmaceuticals-appoints-new-fractional-chief-financial-officer?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/mira-pharmaceuticals-appoints-new-fractional-chief-financial-officer?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","MIRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642643477","title":"BRIEF-Mira Pharmaceuticals - Alan Weichselbaum To Step Down As CFO Effective June 6, 2026 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2642643477","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642643477?lang=en_us&edition=fundamental","pubTime":"2026-06-09 05:17","pubTimestamp":1780953426,"startTime":"0","endTime":"0","summary":"BRIEF-Mira Pharmaceuticals - Alan Weichselbaum To Step Down As CFO Effective June 6, 2026 - SEC FilingJune 8  - Mira Pharmaceuticals Inc MIRA.O:MIRA PHARMACEUTICALS - ALAN WEICHSELBAUM TO STEP DOWN AS CFO EFFECTIVE JUNE 6, 2026 - SEC FILINGMIRA PHARMACEUTICALS - APPOINTS ANDRIY MUSHAK AS FRACTIONAL CFO EFFECTIVE JUNE 6, 2026 - SEC FILINGSource text: [ID:n0001493152-26-027751]Further company coverage: MIRA.O ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260608:nFWN42G13I:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","MIRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642843417","title":"Mira Pharmaceuticals names Andriy Mushak fractional CFO, replacing Alan Weichselbaum","url":"https://stock-news.laohu8.com/highlight/detail?id=2642843417","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642843417?lang=en_us&edition=fundamental","pubTime":"2026-06-09 05:01","pubTimestamp":1780952485,"startTime":"0","endTime":"0","summary":"Mira Pharmaceuticals named Andriy Mushak fractional chief financial officer effective June 6, 2026.Outgoing CFO Alan Weichselbaum leaves the role June 6, 2026; departure not tied to any disagreements over operations, policies, or practices.Mushak is a CPA with more than 20 years of SEC reporting, accounting compliance, and audit experience.He is a partner at LMAM Consulting Group; previously spent over a decade at Baker Tilly US in audit, most recently as a senior manager.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mira Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission ,","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260608:nNDL7m0fXN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MIRA","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640015157","title":"MIRA Pharmaceuticals Secures Unified Global Rights to Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2640015157","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640015157?lang=en_us&edition=fundamental","pubTime":"2026-06-04 20:35","pubTimestamp":1780576512,"startTime":"0","endTime":"0","summary":"MIRA Pharmaceuticals, Inc. ( ($MIRA) ) has shared an announcement. On June 3, 2026, MIRA Pharmaceuticals, Inc. entered into an amended and restated...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/mira-pharmaceuticals-secures-unified-global-rights-to-pipeline?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/mira-pharmaceuticals-secures-unified-global-rights-to-pipeline?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MIRA","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640015227","title":"Mira Pharmaceuticals Inc: Controls Global Development Rights Across Entire Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2640015227","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640015227?lang=en_us&edition=fundamental","pubTime":"2026-06-04 20:03","pubTimestamp":1780574582,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260604:nFWN42C0M8:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MIRA","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640521021","title":"Mira Pharmaceuticals secures worldwide exclusive rights to MIRA-55 and SKNY-1 in amended license deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2640521021","media":"Reuters","labels":["corporation","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640521021?lang=en_us&edition=fundamental","pubTime":"2026-06-04 20:00","pubTimestamp":1780574430,"startTime":"0","endTime":"0","summary":"Mira Pharmaceuticals executed an amended exclusive license with MIRALOGX, securing worldwide exclusive rights to MIRA-55 and SKNY-1.Deal grants global development, commercialization, sublicensing, IP enforcement rights for both assets, tightening control of the company’s pipeline.MIRA-55 is an oral investigational candidate for chronic inflammatory pain; SKNY-1 targets obesity and addiction-related disorders.Amendment leaves previously disclosed core economic terms of existing license arrangements largely unchanged.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260604:nNDL793X6h:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Mira Pharmaceuticals secures worldwide exclusive rights to MIRA-55 and SKNY-1 in amended license deal","news_tag":"corporation,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MIRA","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638688567","title":"MIRA Expands Global Ketamir-2 License for Clinical Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2638688567","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638688567?lang=en_us&edition=fundamental","pubTime":"2026-05-27 20:37","pubTimestamp":1779885424,"startTime":"0","endTime":"0","summary":"An announcement from MIRA Pharmaceuticals, Inc. ( ($MIRA) ) is now available. On May 21, 2026, MIRA Pharmaceuticals amended its exclusive Ketamir-2...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/mira-expands-global-ketamir-2-license-for-clinical-development?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/mira-expands-global-ketamir-2-license-for-clinical-development?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MIRA","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638507708","title":"Mira Pharmaceuticals Inc: Entered Into Amendment No 1 to Exclusive License Agreement With Miralogx Llc - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2638507708","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638507708?lang=en_us&edition=fundamental","pubTime":"2026-05-27 20:08","pubTimestamp":1779883731,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260527:nFWN4240K6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MIRA","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638507050","title":"Mira Pharmaceuticals Inc - Expands Ketamir-2 Patent Portfolio to 10 Major Markets - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2638507050","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638507050?lang=en_us&edition=fundamental","pubTime":"2026-05-27 20:08","pubTimestamp":1779883731,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260527:nFWN4240K6:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","MIRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638507439","title":"Mira Pharmaceuticals expands Ketamir-2 license to worldwide rights across 10 major markets","url":"https://stock-news.laohu8.com/highlight/detail?id=2638507439","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638507439?lang=en_us&edition=fundamental","pubTime":"2026-05-27 20:01","pubTimestamp":1779883291,"startTime":"0","endTime":"0","summary":"Mira Pharmaceuticals expanded its exclusive Ketamir-2 license to worldwide rights under an amended agreement with MIRALOGX.Broader IP coverage spans 10 major markets, supporting global partnering options as Ketamir-2 advances toward Phase 2a in CIPN.The amendment leaves the previously disclosed core economic terms of the original license agreement largely unchanged.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260527:nNDL8dsWB5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MIRA","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638549778","title":"Mira Pharmaceuticals management to meet with Maxim","url":"https://stock-news.laohu8.com/highlight/detail?id=2638549778","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638549778?lang=en_us&edition=fundamental","pubTime":"2026-05-27 00:54","pubTimestamp":1779814484,"startTime":"0","endTime":"0","summary":"Meeting to be held on May 27 hosted by Maxim. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news....","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/mira-pharmaceuticals-management-to-meet-with-maxim-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/mira-pharmaceuticals-management-to-meet-with-maxim-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","MIRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635639740","title":"Mira Pharmaceuticals Q1 net loss narrows to $1.15 million; revenue flat at no revenue","url":"https://stock-news.laohu8.com/highlight/detail?id=2635639740","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635639740?lang=en_us&edition=fundamental","pubTime":"2026-05-15 03:04","pubTimestamp":1778785473,"startTime":"0","endTime":"0","summary":"Mira Pharmaceuticals posted a net loss of $1.15 million, narrowing from $1.78 million a year earlier, while loss per share improved to $0.03 from $0.11.Operating costs fell to $1.1 million from $1.81 million, as general and administrative expense dropped to $578,698 from $1.49 million.Research and development spending climbed to $524,781 from $314,404.Cash declined to $4.82 million from $6.35 million at Dec. 31, while short-term investments edged down to $4.59 million from $4.68 million.Ketamir-2 completed Phase 1 dosing and is being advanced toward a Phase 2a CIPN study in first half 2026, while MIRA-55 and SKNY-1 remained in preclinical development.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mira Pharmaceuticals Inc. published th","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nNDL7wKZ09:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","MIRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635759662","title":"MIRA Pharmaceuticals Reports Positive Phase 1 Ketamir-2 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2635759662","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635759662?lang=en_us&edition=fundamental","pubTime":"2026-05-14 05:14","pubTimestamp":1778706865,"startTime":"0","endTime":"0","summary":"MIRA Pharmaceuticals, Inc. ( ($MIRA) ) has issued an update. MIRA Pharmaceuticals, Inc. reported positive unblinded results from a completed Phase ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/mira-pharmaceuticals-reports-positive-phase-1-ketamir-2-results?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/mira-pharmaceuticals-reports-positive-phase-1-ketamir-2-results?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MIRA","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635275345","title":"Mira Pharmaceuticals publishes investor presentation on Ketamir-2 for chemotherapy-induced peripheral neuropathy","url":"https://stock-news.laohu8.com/highlight/detail?id=2635275345","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635275345?lang=en_us&edition=fundamental","pubTime":"2026-05-14 04:20","pubTimestamp":1778703609,"startTime":"0","endTime":"0","summary":"Mira Pharmaceuticals highlighted Ketamir-2, an oral selective NMDA receptor modulator being developed for chemotherapy-induced peripheral neuropathy, a condition it estimates affects 30%-40% of chemotherapy patients with no FDA-approved treatments.Phase 1 program completed in 56 healthy volunteers with 0 serious adverse events, testing doses up to 600 mg.Phase 2a protocol submission targeted for H1 2026 under an active IND, with enrollment expected to begin in 2026 and first readout expected in Q1 2027.Planned Phase 2a design calls for a randomized, double-blind, placebo-controlled, three-period crossover study in 24 patients, evaluating 150 mg and 300 mg oral doses.Estimated all-in cost for Phase 2a cited at USD 4-6 million, with management describing the company as debt-free.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informatio","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nNDL4VqDyM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MIRA","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635758990","title":"Mira Pharma reports positive Phase 1 results for Ketamir-2 oral NMDA modulator","url":"https://stock-news.laohu8.com/highlight/detail?id=2635758990","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635758990?lang=en_us&edition=fundamental","pubTime":"2026-05-14 04:04","pubTimestamp":1778702687,"startTime":"0","endTime":"0","summary":"Mira Pharmaceuticals reported positive unblinded results from its completed Phase 1 trial of oral Ketamir-2; no future presentation was disclosed.Study met key early-stage objectives, with results supporting a favorable safety and tolerability profile in healthy volunteers.Data also indicated drug exposure consistent with potential once-daily dosing, subject to further clinical testing.Company is preparing to submit Phase 2a materials to FDA to start a mid-stage study in chemotherapy-induced peripheral neuropathy under its active IND.DEA review concluded Ketamir-2 is not classified as a controlled substance, removing a potential regulatory constraint ahead of later-stage development.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mira ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nNDLbZfH5S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","MIRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635943731","title":"Mira announces acceptance of peer-reviewed SKNY-1 manuscript","url":"https://stock-news.laohu8.com/highlight/detail?id=2635943731","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635943731?lang=en_us&edition=fundamental","pubTime":"2026-05-14 00:28","pubTimestamp":1778689697,"startTime":"0","endTime":"0","summary":"Mira Pharmaceuticals (MIRA) announced the acceptance and publication of a peer-reviewed manuscript describing the preclinical pharmacology and acti...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/mira-announces-acceptance-of-peer-reviewed-skny-1-manuscript-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/mira-announces-acceptance-of-peer-reviewed-skny-1-manuscript-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MIRA","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635843227","title":"MIRA highlights SKNY-1 preclinical data in new publication","url":"https://stock-news.laohu8.com/highlight/detail?id=2635843227","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635843227?lang=en_us&edition=fundamental","pubTime":"2026-05-13 20:00","pubTimestamp":1778673639,"startTime":"0","endTime":"0","summary":"MIRA Pharmaceuticals, Inc. ( ($MIRA) ) just unveiled an announcement. On May 13, 2026, MIRA Pharmaceuticals announced that a peer-reviewed manuscri...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/mira-highlights-skny-1-preclinical-data-in-new-publication?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/mira-highlights-skny-1-preclinical-data-in-new-publication?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MIRA","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635030789","title":"Mira Pharmaceuticals reports peer-reviewed preclinical study on obesity candidate SKNY-1","url":"https://stock-news.laohu8.com/highlight/detail?id=2635030789","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635030789?lang=en_us&edition=fundamental","pubTime":"2026-05-13 19:32","pubTimestamp":1778671973,"startTime":"0","endTime":"0","summary":"Mira Pharmaceuticals on May 13, 2026 announced publication of peer-reviewed preclinical research on oral candidate SKNY-1, with results already presented in the journal article.Study reported SKNY-1 produced weight loss in an obesity-model zebrafish study without signs of harmful loss of body mass quality over the short treatment period.Researchers also described improvements in lipid-related measures, lower fat buildup in liver tissue, supported by shifts in appetite-related gene activity.Behavior tests showed reduced compulsive feeding and nicotine-seeking signals, supporting development rationale in obesity and nicotine addiction.Update did not disclose any new or upcoming human clinical trial timelines, leaving near-term value inflection tied to additional preclinical work or future clinical initiation.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-gener","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nNDL39L1r1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","MIRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625600813","title":"Mira Pharmaceuticals investor presentation highlights Ketamir-2 advancing to Phase 2a neuropathic pain trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2625600813","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625600813?lang=en_us&edition=fundamental","pubTime":"2026-04-07 07:17","pubTimestamp":1775517431,"startTime":"0","endTime":"0","summary":"Mira Pharmaceuticals outlined strategy to advance oral drug pipeline targeting neurologic, neuropsychiatric, metabolic disorders.Lead asset Ketamir-2, oral ketamine analog, completed Phase 1 with favorable safety and tolerability.Program slated to move into Phase 2a study in chemotherapy-induced peripheral neuropathy.Presentation states DEA review found Ketamir-2 is not a controlled substance, positioning it as a non-opioid option for neuropathic pain.Pipeline also features SKNY-1 for obesity and smoking cessation, MIRA-55 for anxiety reduction and cognition support in aging.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mira Pharmaceuticals Inc. published the original content used to generate this news brief on April 06, 2026, and is","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260406:nNDL31cxSs:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","MIRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624555998","title":"Mira Pharmaceuticals FY25 net loss widens to $10 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2624555998","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624555998?lang=en_us&edition=fundamental","pubTime":"2026-04-01 06:36","pubTimestamp":1774996574,"startTime":"0","endTime":"0","summary":"Mira Pharmaceuticals posted a net loss of USD 10 million for fiscal 2025.Total operating costs climbed to USD 10 million, driven by higher general and administrative expense.Cash and cash equivalents rose to USD 6 million at Dec. 31, 2025.Mira completed dosing in a Phase 1 trial of Ketamir-2 in healthy volunteers, targeting a Phase 2a study in chemotherapy-induced peripheral neuropathy in the first half of 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mira Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 31, 2026, and is solely responsible for the informat","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260331:nNDLbM3gb5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MIRA","BK4007"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":49,"code":"91000000","status":"200"}]}}